Melanotan II

Unapproved, and linked to new or changing moles and reported melanoma cases. Sold online as a tanning peptide; regulators in several countries warn against it.

Evidence: Limited human research
Half-life: Not known
Sources: 3 cited

Is melanotan II FDA-approved?

Not approved anywhere. Several countries' regulators have issued warnings about it.

Overview

Melanotan II switches on several melanocortin receptors, so it darkens skin and can cause spontaneous erections and appetite loss. It was tested in small trials in the 1990s, including for erectile dysfunction, and led to bremelanotide (PT-141). Dermatologists have reported new or changing moles and cases of melanoma in users, and health agencies in several countries have warned against it.

How it works

It acts on MC1R (skin pigment), MC3R and MC4R (appetite and sexual function) at once, which is why its effects are broad.

How long does melanotan II stay in the body?

Not well established.

What it's studied for

Tanning
Erectile dysfunction (early trials)

Reported side effects

Nausea, flushing
New or darkening moles; reported melanoma cases
Spontaneous erections
Rare kidney problems (case reports)

Sources

The studies and prescribing labels this page is written from.